Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 8 649 JPY 0.42%
Market Cap: 4.7T JPY
Have any thoughts about
Otsuka Holdings Co Ltd?
Write Note

Net Margin
Otsuka Holdings Co Ltd

6.7%
Current
8%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.7%
=
Net Income
151.6B
/
Revenue
2.3T

Net Margin Across Competitors

Country JP
Market Cap 4.7T JPY
Net Margin
7%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 372B USD
Net Margin
17%
Country US
Market Cap 257.3B USD
Net Margin
19%
Country CH
Market Cap 201.7B CHF
Net Margin
20%
Country UK
Market Cap 163B GBP
Net Margin
13%
Country CH
Market Cap 179.6B CHF
Net Margin
35%
Country US
Market Cap 146B USD
Net Margin
7%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Market Cap
4.7T JPY
Industry
Pharmaceuticals

Otsuka Holdings Co., Ltd. is a Japanese pharmaceutical and nutraceutical powerhouse, woven into the fabric of global health and wellness. Founded in 1964, the company has consistently focused on the discovery, development, and commercialization of innovative products aimed at tackling unaddressed medical needs. Otsuka's broad portfolio includes prescription drugs, particularly in the areas of psychiatry, neurology, and oncology, complemented by a robust range of consumer healthcare products such as drinks and nutritional supplements. With a commitment to research and development, the company invests significantly in innovative drug solutions, resulting in a legacy marked by breakthroughs such as Abilify, a treatment for schizophrenia and bipolar disorder, and an array of lifestyle products that support overall well-being. For investors, Otsuka Holdings presents an intriguing blend of stability and growth potential. Its diversified business model mitigates dependence on any single market segment. The company’s strong financial foundation, supported by solid revenue from both its pharmaceutical and consumer health divisions, highlights its resilience even in challenging economic conditions. As Otsuka continues to expand its global footprint, particularly in emerging markets and through strategic partnerships, it positions itself to capitalize on the growing demand for innovative therapies and nutritional products. The company’s robust commitment to sustainability and social responsibility further enhances its attractiveness to investors looking for long-term value. With a vision centered on health, innovation, and quality of life, Otsuka stands as a formidable player in the healthcare landscape, poised for growth while delivering on its mission to create new products for a healthier world.

Intrinsic Value
9 509.75 JPY
Undervaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.7%
=
Net Income
151.6B
/
Revenue
2.3T
What is the Net Margin of Otsuka Holdings Co Ltd?

Based on Otsuka Holdings Co Ltd's most recent financial statements, the company has Net Margin of 6.7%.